Prashant Jagannath Chaudhari, Aditya Ramchandra Nemade and Atul Arun Shirkhedkar
RSC Adv., 2024,14, 33384-33417
From themed collection:
2024 Reviews in RSC Advances
Abstract
Essential structural motifs for design of Lead against VEGFR-2.
Dalia R. Aboshouk, M. Adel Youssef, Mohamed S. Bekheit, Ahmed R. Hamed and Adel S. Girgis
RSC Adv., 2024,14, 5690-5728
From themed collection:
2024 Reviews in RSC Advances
Abstract
VEGF, an important category of tyrosine kinases, and its receptors (VEGFR) are hyper-activated in different cancers. The recently reported indolyl analogs with potential antineoplastic and VEGFR inhibitory properties are highlighted.
Mohamed S. Shehda, Aya M. Almatary, Mohamed S. H. Salem, Mohamed H. Aboutaleb, Shinobu Takizawa, Yasmine M. Abdel Aziz, Magda A. A. El-Sayed and Ranza Elrayess
RSC Med. Chem., 2026, Advance Article
From themed collection:
Kinases
Abstract
Sorafenib-inspired benzofuran hybrids were designed as VEGFR-2 inhibitors; lead 7g showed potent, selective anti-HCC activity, inducing cell cycle arrest and apoptosis, nominating it as a promising HCC-targeted lead.
Hazem Elkady, Osama A. El-Dardir, Alaa Elwan, Mohammed S. Taghour, Hazem A. Mahdy, Mohammed A. Dahab, Eslam B. Elkaeed, Bshra A. Alsfouk, Ibrahim M. Ibrahim, Dalal Z. Husein, Elsayed E. Hafez, Amira M. G. Darwish, Ahmed M. Metwaly and Ibrahim H. Eissa
RSC Adv., 2023,13, 27801-27827
Abstract
Design, synthesis, in vitro and in silico studies of novel thiazolidine-2,4-diones as antitumor VEGFR-2 inhibitors with apoptotic activities.
Reda R. Mabrouk, Arafa Musa, Maged Mohammed Saleh Al Ward, Shaimaa Hussein, Ahmed K. B. Aljohani, Mohamed Ayman El-Zahabi and Alaa Elwan
RSC Adv., 2025,15, 29593-29612
Abstract
A novel series of quinazoline-based compounds were designed and synthesized as modified analogues to certain known VEGFR-2 inhibitors, as an extension of our work on the design and synthesis of new VEGFR-2 inhibitors.